PI
CRSP icon

PFG Investments’s CRISPR Therapeutics CRSP Stock Holding History

PFG Investments’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$468K Sell
8,587
-339
-4% -$17.9K 0.02% 701
2026
Q1 		$425K Sell
8,926
-100
-1% -$5.27K 0.02% 678
2025
Q4 		$473K Sell
9,026
-20
-0.2% -$1.2K 0.02% 593
2025
Q3 		$586K Sell
9,046
-3,850
-30% -$221K 0.03% 501
2025
Q2 		$627K Buy
12,896
+2,487
+24% +$96.2K 0.04% 443
2025
Q1 		$354K Sell
10,409
-194
-2% -$8.22K 0.02% 622
2024
Q4 		$417K Buy
10,603
+952
+10% +$45K 0.03% 577
2024
Q3 		$453K Sell
9,651
-755
-7% -$38.3K 0.03% 530
2024
Q2 		$562K Sell
10,406
-437
-4% -$25.3K 0.04% 410
2024
Q1 		$739K Buy
+10,843
New +$776K 0.04% 410

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GP
GSK plc London $602M AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

PFG Investments's CRSP Position: Q2 2026 in Review

PFG Investments reduced its CRISPR Therapeutics (CRSP) stake by 3.8% in Q2 2026, selling an estimated $17.9K and leaving 8,587 shares worth $468K. The position accounts for 0.02% of the portfolio, ranked #701.

PFG Investments first reported a position in CRSP in Q1 2024 and has held it in 10 quarters since. The position peaked at $739K in Q1 2024. 521 funds tracked by Wall St. Rank hold CRSP as of Q2 2026.

  • PFG Investments held 8,587 shares of CRISPR Therapeutics worth $468K as of Q2 2026.
  • PFG Investments sold 339 CRISPR Therapeutics shares in Q2 2026, an estimated $17.9K.
  • CRISPR Therapeutics made up 0.02% of PFG Investments's portfolio in Q2 2026, its #701 holding.
  • PFG Investments first reported a position in CRISPR Therapeutics in Q1 2024 and has held it in 10 quarters since.
  • PFG Investments's CRISPR Therapeutics position peaked at $739K in Q1 2024.
  • 521 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2026.

Based on PFG Investments's 13F filing for Q2 2026, filed 23 Jul 2026.